Use

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an acquired, immune-mediated condition affecting peripheral nerves and nerve roots, characterized by electrodiagnostic features of demyelination and chronic onset leading to significant disability. CIDP is important to recognize as it is treatable with immunomodulating therapies. A subset of patients with suspected CIDP have autoantibodies targeting nodal-paranodal proteins like neurofascin-155 and contactin-1. These patients share immunopathological mechanisms, clinical features, and treatment responses distinct from classic CIDP. Detection of these antibodies, especially NF155 IgG4 and CNTN1 IgG, aids in diagnosing and tailoring treatment accordingly.